



Review Article

Heparin-binding Protein as a Diagnostic and Prognostic Marker of Infections: A Systematic Review and Meta-analysis

Wanchun Yang¹ and Wei Dong².

¹ Department of Emergency, Hami Red Star Hospital, No. 19 Qianjin East Road, Yizhou District, Hami City, 839000, China.

² Intensive Care Medical Center, Hami Red Star Hospital, No. 19 Qianjin East Road, Yizhou District, Hami City, 839000, China.

Competing interests: The authors declare no conflict of Interest.

Abstract. Heparin-binding protein (HBP) is a granule protein derived from neutrophils, located in secretory vesicles and neutrophilic granules, also known as cationic antimicrobial protein of 37 kDa (CAP37) or azurocidin. This study evaluates the diagnostic and prognostic value of HBP levels in relation to infection, organ dysfunction, and mortality in adult patients. A systematic review and meta-analysis were conducted by searching PubMed, Web of Science, EMBASE, and the Cochrane Database from their inception through June 2024. Original studies assessing HBP levels' diagnostic and prognostic utility in predicting infection and disease severity in critically ill adult patients were included. The primary outcome was the diagnostic and predictive role of HBP in infection and severity. The Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool was used to evaluate bias risk. A total of 56 studies involving 11,486 patients were included. Pooled analysis showed HBP had a sensitivity of 0.87 (95% CI, 0.82–0.91), specificity of 0.87 (95% CI, 0.79–0.92), and an AUC of 0.93 (95% CI, 0.91–0.95) for infection diagnosis. For prognostic assessment, sensitivity was 0.77 (95% CI, 0.74–0.80), specificity was 0.72 (95% CI, 0.68–0.76), and AUC was 0.81 (95% CI, 0.78–0.85). HBP outperformed procalcitonin (PCT), C-reactive protein (CRP), and white blood cell count (WBC) in diagnosing and predicting critical illness. No publication bias was detected. HBP demonstrates high sensitivity and specificity for diagnosing infections in critically ill adult patients. Additionally, it effectively predicts disease progression, including organ dysfunction and mortality, surpassing traditional biomarkers such as PCT, CRP, and WBC. All that cannot be true for subjects with severe neutropenia.

Keywords: Heparin-binding protein; Systematic review, Meta-analysis, Diagnosis, Prognosis, Infectious disease, Sepsis, Organ failure, Mortality.

Citation: Yang W., Dong W. Heparin-binding protein as a diagnostic and prognostic marker of infections: A systematic review and meta-analysis. *Mediterr J Hematol Infect Dis* 2025, 17(1): e2025029, DOI: <http://dx.doi.org/10.4084/MJHID.2025.029>

Published: May 01, 2025

Received: December 25, 2024

Accepted: April 11, 2025

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by-nc/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Correspondence to: Wei Dong. Intensive Care Medical Center, Hami Red Star Hospital, No. 19 Qianjin East Road, Yizhou District, Hami City, 839000, China. E-mail: hamiweidong@sina.com

Introduction. Critically ill diseases, such as sepsis, trauma, and multiple organ dysfunction, are life-threatening conditions.^{1,2} It is one of the main determinants of the mortality rate in the intensive care unit (ICU). Early identification of critically ill patients with severe infections or poor outcomes is an ongoing clinical challenge for intensive care unit doctors. Blood biomarkers, such as PCT (procalcitonin), WBC, and

CRP, may provide information for severe infections.³ Sequential Organ Failure Assessment (SOFA) score and Acute Physiology and Chronic Health Evaluation (APACHE II) have been validated for risk stratification of critical illness.^{4,5} However, no single biomarker in Critically ill has been identified as a gold standard.

Heparin-binding protein (HBP) is a granule protein derived from neutrophils and located in secretory vesicles and neutrophilic granules, which is also called cationic antimicrobial protein of 37 kDa (CAP37) or leukocidin.⁶ In neutrophils, HBP contributes to the regulation of endothelial permeability. HBP was considered a promising novel biomarker in infectious diseases due to the role of HBP in intravascular neutrophil activation.^{7,8} In addition, HBP has been considered a predictive biomarker for the progression of organ dysfunction induced by sepsis, such as circulatory failure, respiratory failure, and acute kidney injury.⁹ There is also a growing body of studies showing that a high concentration of HBP in plasma is associated with disease severity, especially mortality and organ failure.⁹⁻¹² The level of HBP in the blood of healthy people is very low, generally no more than 10 ng/ml. When an infection occurs, HBP levels change with the severity of the disease. Multiple studies have indicated that HBP is associated with various types of infection, showing elevated levels across different infections.¹³ Moreover, it is considered to possess good predictive value in forecasting the occurrence, progression, and prognosis of severe infections and septic shock. In addition, recently increasing studies have illustrated that HBP has important predictive value for the prognosis of the critically ill.^{12,14} Increased levels of coronary sinus HBP could serve as valuable indicators for predicting myocardial injury-related cardiogenic shock after cardiac surgery.¹¹ A high level of HBP in plasma upon ICU admission is connected to occurrences of respiratory and circulatory failure throughout the ICU period, which correlates with an elevated 30-day mortality rate.¹⁵ Hence, HBP may serve as an effective biomarker for rapid clinical assessment of critical illness. However, comprehensive evaluation regarding the diagnostic efficacy of infection and prognostic ability of HBP in critically ill adult patients was warranted. Therefore, the role of HBP in the diagnosis of infection and the predictive value in critically ill adult patients were evaluated in this systematic review and meta-analysis.

Methods

Search strategy. A comprehensive systematic search was performed across PubMed, Embase, Scopus, and the Cochrane Library using a combination of Medical Subject Headings (MeSH) terms and free-text keywords. The following search terms were included: "Heparin-Binding Protein" (HBP), "Sepsis," "Diagnostic Accuracy," and "Biomarkers." Boolean operators

(AND/OR) were applied for optimal search sensitivity. The detailed search strategy, including full Boolean logic and MeSH terms, is provided in Supplementary

Study Selection. Two researchers screened the titles and abstracts of all retrieved papers by themselves. The following inclusion criteria were used: (1) study participants (adults ≥ 18 years old), (2) intervention (measurements of HBP), (3) diagnosis performance in infection or prognostic performance in critically ill of HBP levels compared to other potential biomarkers, (4) The data available from the studies included were sufficient to create a 2×2 contingency table, which was either obtained from the original article or derived from the provided dataset or figures. Meeting abstracts, editorials, reviews, letters, case reports, and animal and cell experiments were excluded. Full-text papers were obtained if either of the researchers argued that the abstract and title were suitable. After obtaining the full papers of potentially relevant studies, two researchers independently evaluated each study's eligibility on the basis of the inclusion/exclusion criteria. Full-text papers of screened titles and abstracts in accordance with the inclusion criteria were assessed for final eligibility. The conflicting viewpoints on research eligibility were resolved through consensus negotiations or by seeking input from independent researchers (**Figure 1**).

Data extraction and quality assessment. Two investigators independently extracted data by applying the same standard to record the study design, publication year, country, number of study participants, participant clinical characteristics, HBP levels, biomarkers other than HBP, study outcomes, and so on. Furthermore, among the included studies, data were extracted to establish a 2×2 contingency table to evaluate the ability of HBP to diagnose infection in disease and predict prognosis, such as mortality and organ failure, in adult patients.

The risk of bias in the included studies was evaluated by two independent reviewers applying the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool.¹⁷ We evaluated with QUADAS-2 four potential areas of bias. These four areas include: (1) Patient selection, (2) Evaluation test, (3) Gold standard, and (4) Flow and timing. "yes", "no," or "unclear" were scored in each criterion.

Evidence synthesis. A pooled sensitivity, specificity, and AUC with the corresponding 95% CIs were calculated by applying a bivariate random-effects meta-analysis model. A hierarchical summary receiver operating characteristic (ROC) curve model was performed, and the area under the summary ROC curve with CIs was evaluated from different diagnostic and prognostic studies. In addition, the extent of heterogeneity of the

Detailed Search Strategy:

- PubMed
- Embase
- Scopus
- Cochrane Library

Search Terms and Boolean Logic:

("Heparin-Binding Protein" OR "HBP" OR "HBP biomarker") AND ("Sepsis" OR "Severe sepsis" OR "Septic shock") AND ("Diagnostic Accuracy" OR "Sensitivity" OR "Specificity" OR "ROC Curve")

MeSH Terms Used:

- "Sepsis"[MeSH]
- "Heparin-Binding Protein"[MeSH]
- "Biomarkers"[MeSH]
- "Diagnostic Tests, Routine"[MeSH]

Filters Applied:

- **Language:** English
- **Study Type:** Clinical trials, cohort studies, case-control studies
- **Publication Date:** From 2009 to 2024

Figure 1. A flow diagram of included studies for systematic review.

included studies was quantified by the I² statistic, and subgroup analyses were conducted to find potential sources of heterogeneity. Study design, sample size, time of study, and country were included in predefined subgroups. Potential publication bias was assessed by Deeks' test.¹⁸ The CIs and p-values were calculated analytically. Statistical analyses were performed by applying STATA MP17 and R software. All statistical tests were conducted with a two-tailed approach, and the statistical significance threshold was defined as $p < 0.05$.

Results. A flow diagram of included studies for systematic review was reported in **Figure 1**, which demonstrates the selection process of included studies. One thousand twenty-six studies were retrieved in our database search, and 418 studies were excluded after removing duplications. Moreover, 499 studies were further excluded after screening the titles and abstracts. Therefore, 56 studies were included after a full-text review,^{6,10,11,15,19-70} and 23 studies were excluded. **Table 1** displays the features of the included studies. The included studies were published from 2009 to 2024. Twenty studies were performed in China, nineteen studies were conducted in Sweden, and seventeen studies

were conducted in other countries. All included studies evaluated the role of HBP in diagnosing infection and predicting clinical outcomes in critically ill adult patients. Overall, the aggregate study population included a total of 11486 adult patients with infectious diseases and critically ill patients. HBP levels were used to elevate the role in adult patients. The mean age ranged between 18 and 94 years. In addition, there were 24 studies evaluating the diagnostic role of HBP, 29 studies assessing the prognostic role of HBP, and three studies evaluating both the diagnostic and predictive role of HBP. Because some researchers suggested diagnostic or prognostic accuracy separately for patients in studies, these studies were divided into two or three parts. Therefore, 38 dataset analyses were performed in the diagnosis study, and 45 dataset analyses were performed in the prognosis study.

Risk of bias assessment. Problematic QUADAS items were: 1. Was a consecutive or random sample of patients enrolled? 2. Was a case-control design avoided? 3. Did the study avoid inappropriate exclusions? 4. Were the index test results interpreted without knowledge of the results of the reference standard? 5. If a threshold was

Table 1. Characteristics of the included studies.





Figure 2. Characteristic curves of HBP, PCT, CRP, and WBC for diagnosing infection. HBP: Heparin-binding protein; PCT: Procalcitonin; CRP: C-reactive protein; WBC: White Blood Cell.

used, was it pre-specified? 6. Is the reference standard likely to correctly classify the target condition? 7. Were the reference standard results interpreted without knowledge of the results of the index test? 8. Was there an appropriate interval between index test(s) and reference standard? 9. Did all patients receive a reference

standard? 10. Did patients receive the same reference standard? 11. Were all patients included in the analysis? *Accuracy of HBP in diagnosing infection.* For the accuracy of HBP in diagnosing infection, HBP has the best discriminative power to differentiate infection from non-infection. The area under the summary ROC curve was 0.93 (95% CI, 0.91–0.95) for HBP (**Figure 2**), 0.85 (95% CI, 0.81–0.88) for PCT, 0.83 for CRP (95% CI, 0.79–0.86), and 0.80 (95% CI, 0.76–0.83) for WBC. Sensitivity and specificity of HBP for diagnosing infectious disease were 0.87 (95% CI, 0.82–0.91) and 0.87 (95% CI, 0.79–0.92), 0.81 (95% CI, 0.71–0.88) and 0.76 (95% CI, 0.67–0.83) for PCT, 0.74 (95% CI, 0.65–0.81) and 0.78 (95% CI, 0.72–0.83) for CRP, 0.72 (95% CI, 0.64–0.79) and 0.78 (95% CI, 0.62–0.89) for WBC.

The value of HBP levels in predicting organ failure in critically ill adult patients. The utility of HBP levels was assessed in 12 studies to predict the future occurrence of organ failure. These studies displayed significantly higher HBP levels in adult patients who subsequently developed organ failure compared to those patients without organ failure. In our study, the area under the summary ROC curve was 0.84 (95% CI, 0.80–0.87) (**Figure 3**) for HBP in predicting organ failure, and sensitivity and specificity of HBP for diagnosing organ failure was 0.80 (95% CI, 0.75–0.84) and 0.72 (95% CI, 0.62–0.80). Increased plasma concentrations of HBP are correlated with an imminent risk of developing sepsis, circulatory failure, and the severity of infection in adult patients.¹⁰ Increased HBP levels upon admission to the




Figure 3. reports the characteristic curves of HBP for prognosing organ failure in infectious diseases and other diseases. HBP: Heparin-binding protein.




Figure 4. SROC curve.

intensive care unit were linked to the development of severe acute kidney injury within the initial 7 days.⁷¹

Value of HBP levels in predicting mortality in adult patients. All 14 studies evaluating the value of HBP level determination in predicting mortality in adult patients showed a significant elevation of HBP levels in non-survivors compared with that in survivors. The area under the summary ROC curve was 0.79 (95% CI, 0.75–0.82) for HBP (**Figure 4**). The sensitivity and specificity of HBP for diagnosing mortality were 0.75 (95% CI, 0.70–0.79) and 0.70 (95% CI, 0.64–0.76). A study showed that patients with sepsis with a decreased HBP greater than 50% in 48 hours had a greater than 90%

chance of survival. However, patients with sepsis with decreased HBP in 48 hours less than 4% had a nearly 90% 30-day all-cause mortality rate.²⁷ Conversely, one study showed that there was no association between a single HBP level and 28-day mortality.³⁵

Value of HBP levels in predicting the outcome of critically ill adult patients. The association between HBP level and the outcome of critically ill adult patients was evaluated in our systematic review and meta-analysis. The results suggested that all of those with worsening conditions (including mortality and organ dysfunction) had higher HBP levels than those in stable or healthy state. In addition to mortality and organ dysfunction, the association between HBP level and the severity of diseases in adult patients has been reported in many studies. One study reported that HBP is an important biomarker in patients with ST-segment elevation typical of myocardial infarction.³² Another study demonstrated that HBP could predict the risk of severe acute pancreatitis in advance.³⁸ In our present study, the area under the summary ROC curve was 0.81 (95% CI, 0.78–0.85) for HBP, and the sensitivity and specificity of HBP for prognosis in adult patients were 0.77 (95% CI, 0.74–0.80) and 0.72 (95% CI, 0.68–0.76) (**Figure 5**). However, one study reported that there was no association between HBP level and disease severity in patients with acute pancreatitis.⁵⁷




Figure 5. The characteristic curves of HBP, PCT, CRP, and WBC for predicting the outcome of critically ill. HBP: Heparin-binding protein; PCT: Procalcitonin; CRP: C-reactive protein; WBC: White Blood Cell.

Subgroup analysis. Subgroup analysis of retrospective studies (AUROC, 0.94) showed a better diagnostic

accuracy of infection for HBP than that prospective (AUROC, 0.91). HBP tends to conduct better before 2020 (AUROC, 0.97) than after 2020 (including 2020) studies (AUROC, 0.90). Studies were performed on different countries that displayed similar accuracy in identifying infectious diseases. Regarding sample size, the subgroup analysis of studies from less than 200 demonstrated HBP has better discriminative power to differentiate infectious disease and non-infectious disease than that greater than 200. However, for the prognostic role of HBP in our present study, the subgroup analysis of studies from different study types, study years, and sample sizes illustrated similar results. HBP showed a better prognostic ability than Sweden and other countries in our present subgroup analysis.

Significant heterogeneity was observed in the overall analysis and subgroup analyses. However, no evidence of a threshold effect was found, which indicated that a specific cutoff point did not influence the variability in the results.

Discussion. In our systematic review and meta-analysis, we found that HBP was more accurate biomarkers for infection than CRP, PCT and WBC levels. In addition, HBP also showed good predictive ability for prognosis in critical illness, especially mortality and organ failure.

For clinicians, the early identification of infections remains a challenge. Due to the emergence of antibiotic resistance, it is widely agreed that antibiotics should not be prescribed for every suspected infection. Thus, a better specific biomarker for infection would be most beneficial. HBP is a promising, innovative biomarker for predicting sepsis and sepsis-induced organ failure, which is derived from neutrophils and was first reported by Adam Linder.¹⁰ Based on the predefined protocol, in our present systematic review and meta-analysis, which included 56 studies from several countries, we demonstrated the role of HBP in the diagnosis of infectious diseases and the development of organ failure and mortality in critically ill adult patients. The plasma HBP levels were detected in a prospective study, which included 233 subjects and was performed in 2009 to investigate human infection.¹⁰ The study concluded that there was a strong association between high HBP levels and infection or the development of sepsis with organ dysfunction.¹⁰ After that, HBP could be considered a useful clinical marker for infectious diseases, including sepsis. In our present study, we have summarized the diagnostic efficacy of HBP in infectious diseases. We illustrated that HBP had the best discriminative capability to distinguish infectious diseases from non-infectious diseases when compared with PCT, CRP, or WBC. As the application of biomarkers and validated clinical scoring systems becomes more prevalent in clinical practice, there has been a surge of interest in the diagnostic value of their combined utilization. Several

studies have reported that HBP was combined with another biomarker to diagnose sepsis.^{10,21,27,29,72} Combining HBP, PCT, and lactate may raise the diagnostic role compared to single biomarkers.⁶⁴ Therefore, combining HBP with existing biomarkers or validated clinical scoring systems could improve diagnostic accuracy for infection.

Early elevation of HBP is involved in the severity of adult patients.³⁵ Significantly increased HBP levels are related to a substantially elevated risk for complications in adult patients.⁴³ Several studies have demonstrated that most patients with aggravation of the disease have an increased HBP level ranging from 11 to 266 ng/mL.^{11,56} Previous studies have also demonstrated that HBP serves as a significant predictor of mortality. One study showed that plasma HBP greater than 13.47 ng/mL was related to increased deceased patients (died), with an AUC of 0.81, a sensitivity of 0.90, and a specificity of 0.74.¹⁹ Moreover, HBP is utilized as a diagnostic and monitoring biomarker in clinical settings to assess organ dysfunction resulting from sepsis.⁴³ However, HBP also has displayed a certain predictive role in organ failure in infectious diseases and other diseases.^{52,56,60} Linder et al. illustrated the predictive and diagnostic role of HBP in 2009.¹⁰ The study showed that the level of HBP increased at least 12 hours before signs of organ dysfunction at a cutoff value of 15 ng/mL in severe sepsis. HBP is increased prior to the development of organ failure in COVID-19.⁴⁶ In addition, increased plasma levels of HBP at ICU admission were independently related to multiple organ dysfunction syndrome (MODS) and early death after resuscitation from cardiac arrest.⁵⁴ In our meta-analysis, we synthesized the current evidence to display how HBP can help clinically in the monitoring of organ dysfunction in infectious diseases and other diseases. HBP plays a significant role in the pathogenesis of organ dysfunction in sepsis, specifically by causing an increase in capillary permeability.⁷³ This mechanism helps explain why HBP is a more effective prognostic biomarker than CRP and PCT in the detection of organ dysfunction in sepsis. In addition, some studies indicated that HBP not only predicts mortality and organ failure but also provides some indication of disease progression. One study confirmed that HBP contributed to the early identification of COPD, which illustrated that the level of HBP in the acute exacerbation group (147 ng/ml) is higher than that in the stable group (50.69 ng/ml).²⁶ In another study, elevated levels of coronary sinus HBP were helpful markers for predicting myocardial injury-related cardiogenic shock after cardiac surgery.¹¹ However, more large clinical studies are needed to establish the optimal cutoff for HBP clearance in predicting organ dysfunction and mortality.

To the best of our knowledge, the present study stands as the most comprehensive meta-analysis to date, effectively synthesizing the existing data on the role of

HBP in adult patients, which includes the diagnosis of infection and the prognosis of critically ill adult patients.^{72,74,75} In a previous systematic review and meta-analysis, HBP had a better diagnostic role in identifying sepsis among patients presenting with signs of systemic infection than PCT and CRP, which included 26 studies published up to 2019.⁷⁴ In our present study, we assessed the diagnostic capability of HBP for infectious diseases and evaluated its prognostic potential in predicting critically ill outcomes, which included 56 studies up to 2024. Collectively, our findings revealed that HBP illustrates not only both high sensitivity and specificity in the identification of infectious diseases but also a high prognostic role in the identification of the critically ill. In terms of clinical significance, HBP serves as a crucial diagnostic aid in detecting and ruling out infectious diseases among patients presenting with signs and symptoms of infection.³¹ In addition, HBP levels are increased before the development of aggravation of disease, including organ dysfunction and mortality.⁵⁶ Moreover, this will probably lead to improved outcomes for adult patients with infectious diseases and critically ill adult patients. All the articles reported

As highlighted by Fisher et al. (2022),⁷⁶ variations influence the dynamics of circulating HBP levels in neutrophil activation and mobilization, raising concerns about its reliability in immunocompromised patients. Moreover, Chen and Ma (2024)⁷⁷ emphasize that alternative infection markers may be necessary for this patient population to enhance early detection and differentiation between infectious and non-infectious

causes of fever and inflammation. Given these limitations, clinicians should be cautious when interpreting HBP levels in patients with neutropenic fever, frequently found in hematologic malignancies, and consider complementary biomarkers and clinical scoring systems to improve diagnostic accuracy.⁷⁸

However, our present study, which also excluded neutropenic patients, has several limitations. First, variations across countries, study types, and years may contribute to heterogeneity in the pooled outcomes, potentially diminishing the precision of sensitivity and specificity measurements. Second, this study only included studies in which the language is English, and more studies in other languages are needed in future studies. Furthermore, there is limited usefulness in pooling studies comparing healthy adults and cases with studies looking at a cohort of patients with a reasonable likelihood of having the target condition.

Conclusions. While HBP has demonstrated significant utility as a biomarker for infections in critically ill patients, its reliability is reduced in individuals with hematologic malignancies, particularly those experiencing severe neutropenia. Patients with conditions such as leukemia or those undergoing intensive chemotherapy often exhibit depleted neutrophil counts, which can significantly impact the release and detection of HBP. To enhance its clinical applicability, standardized cutoff values and future multicenter studies are recommended.

References:

1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM et al: The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *Jama* 2016, 315(8):801-810.
<https://doi.org/10.1001/jama.2016.0287>
PMid:26903338 PMCID:PMC4968574
2. Cole E, Gillespie S, Vulliamy P, Brohi K: Multiple organ dysfunction after trauma. *The British journal of surgery* 2020, 107(4):402-412.
3. Schuetz P, Wirz Y, Sager R, Christ-Crain M, Stolz D, Tamm M, Bouadma L, Luyt CE, Wolff M, Chastre J et al: Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. *The Lancet Infectious diseases* 2018, 18(1):95-107.
[https://doi.org/10.1016/S1473-3099\(17\)30592-3](https://doi.org/10.1016/S1473-3099(17)30592-3)
PMid:29037960
4. Lambden S, Laterre PF, Levy MM, Francois B: The SOFA score-development, utility and challenges of accurate assessment in clinical trials. *Critical care (London, England)* 2019, 23(1):374.
<https://doi.org/10.1186/s13054-019-2663-7>
PMid:31775846 PMCID:PMC6880479
5. Czajka S, Ziębińska K, Marzenko K, Posmyk B, Szczepańska AJ, Krzych Ł J: Validation of APACHE II, APACHE III and SAPS II scores in in-hospital and one year mortality prediction in a mixed intensive care unit in Poland: a cohort study. *BMC anesthesiology* 2020, 20(1):296.
<https://doi.org/10.1186/s12871-020-01203-7>
PMid:33267777 PMCID:PMC7709291
6. Kahn F, Tverring J, Mellhammar L, Wetterberg N, Bläckberg A, Studahl E, Hadorn N, Kahn R, Nuesch S, Jent P et al. Heparin-Binding Protein as a Prognostic Biomarker of Sepsis and Disease Severity at the Emergency Department. *Shock (Augusta, Ga)* 2019, 52(6):e135-e145.
<https://doi.org/10.1097/SHK.0000000000001332>
PMid:30807529
7. Honore PM, De Bels D, Barreto Gutierrez L, Redant S, Spapen HD: Heparin-binding protein in sepsis: player! predictor! positioning? *Annals of intensive care* 2019, 9(1):71.
<https://doi.org/10.1186/s13613-019-0546-3>
PMid:31222522 PMCID:PMC6586730
8. Doherty DE, Nakano J, Nakano K: Neutrophil-derived heparin-binding protein: a monocyte-specific chemoattractant that induces monocyte migration into rabbit lungs in vivo. *Chest* 1999, 116(1 Suppl):34s-35s.
https://doi.org/10.1378/chest.116.suppl_1.34S-a
PMid:10424582
9. Fisher J, Linder A: Heparin-binding protein: a key player in the pathophysiology of organ dysfunction in sepsis. *Journal of internal medicine* 2017, 281(6):562-574.
<https://doi.org/10.1111/joim.12604>
PMid:28370601
10. Linder A, Christensson B, Herwald H, Björck L, Åkesson P: Heparin-binding protein: an early marker of circulatory failure in sepsis. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2009, 49(7):1044-1050.
<https://doi.org/10.1086/605563>
PMid:19725785
11. Pan T, Long GF, Chen C, Zhang HT, Wang JX, Ahaskar A, Chen HB, Wang DJ: Heparin-binding protein measurement improves the prediction of myocardial injury-related cardiogenic shock. *BMC cardiovascular disorders* 2020, 20(1):124.
<https://doi.org/10.1186/s12872-020-01406-3>
PMid:32156261 PMCID:PMC7065315
12. Linder A, Åkesson P, Inghammar M, Treutiger CJ, Linnér A, Sundén-Cullberg J: Elevated plasma levels of heparin-binding protein in intensive care unit patients with severe sepsis and septic shock. *Critical care (London, England)* 2012, 16(3):R90.

- <https://doi.org/10.1186/cc11353>
PMid:22613179 PMCID:PMC3580636
13. Linder A, Soehnlein O, Åkesson P: Roles of heparin-binding protein in bacterial infections. *Journal of innate immunity* 2010, 2(5):431-438.
<https://doi.org/10.1159/000314853>
PMid:20505311
 14. Tverring J, Nielsen N, Dankiewicz J, Linder A, Kahn F, Åkesson P: Repeated measures of Heparin-binding protein (HBP) and procalcitonin during septic shock: biomarker kinetics and association with cardiovascular organ dysfunction. *Intensive care medicine experimental* 2020, 8(1):51.
<https://doi.org/10.1186/s40635-020-00338-8>
PMid:32910266 PMCID:PMC7483682
 15. Tydén J, Herwald H, Sjöberg F, Johansson J: Increased Plasma Levels of Heparin-Binding Protein on Admission to Intensive Care Are Associated with Respiratory and Circulatory Failure. *PLoS one* 2016, 11(3):e0152035.
<https://doi.org/10.1371/journal.pone.0152035>
PMid:27007333 PMCID:PMC4805239
 16. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE et al: The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ (Clinical research ed)* 2021, 372:n71.
<https://doi.org/10.1136/bmj.n71>
PMid:33782057 PMCID:PMC8005924
 17. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM: QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Annals of internal medicine* 2011, 155(8):529-536.
<https://doi.org/10.7326/0003-4819-155-8-201110180-00009>
PMid:22007046
 18. Deeks JJ, Macaskill P, Irwig L: The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. *Journal of clinical epidemiology* 2005, 58(9):882-893.
<https://doi.org/10.1016/j.jclinepi.2005.01.016>
PMid:16085191
 19. Acar T, Ertekin B, Yortanlı M, Koçak S: Prognostic value of heparin-binding protein for mortality in severe COVID-19 pneumonia. *Biomarkers in medicine* 2022, 16(13):981-991.
<https://doi.org/10.2217/bmm-2022-0265>
PMid:36052658 PMCID:PMC9443788
 20. Akın Şen İ, Karaşahin Ö, Şebin E, Şen C: Use of azurocidin (heparin binding protein) and interleukin-1ß as prognostic indicators in COVID-19 patients. *European Journal of Inflammation* 2022, 20.
<https://doi.org/10.1177/1721727X221105129>
PMCID:PMC9152632
 21. Bergquist M, Samuelsson L, Larsson A, Tydén J, Johansson J, Lipcsey M: TNFR1, TNFR2, neutrophil gelatinase-associated lipocalin and heparin binding protein in identifying sepsis and predicting outcome in an intensive care cohort. *Scientific reports* 2020, 10(1):15350.
<https://doi.org/10.1038/s41598-020-72003-9>
PMid:32948801 PMCID:PMC7501293
 22. Cai R, Li H, Tao Z: Heparin-binding protein and procalcitonin in the diagnosis of pathogens causing community-acquired pneumonia in adult patients: a retrospective study. *PeerJ* 2021, 9:e11056.
<https://doi.org/10.7717/peerj.11056>
PMid:33763308 PMCID:PMC7958890
 23. Chalupa P, Beran O, Herwald H, Kaspříková N, Holub M: Evaluation of potential biomarkers for the discrimination of bacterial and viral infections. *Infection* 2011, 39(5):411-417.
<https://doi.org/10.1007/s15010-011-0126-4>
PMid:21720792
 24. Dankiewicz J, Linder A, Annborn M, Rundgren M, Friberg H: Heparin-binding protein: an early indicator of critical illness and predictor of outcome in cardiac arrest. *Resuscitation* 2013, 84(7):935-939.
<https://doi.org/10.1016/j.resuscitation.2013.01.006>
PMid:23318914
 25. Dhaifalah I, Andrys C, Drahosova M, Musilova I, Adamik Z, Kacerovsky M: Azurocidin levels in maternal serum in the first trimester can predict preterm prelabor rupture of membranes. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet* 2014, 27(5):511-515.
<https://doi.org/10.3109/14767058.2013.820698>
PMid:23808364
 26. Dong Y, Zhou X, Zhang Y, Liu Y, Zhou X, Ren G, Li Q: Application Value of Blood Heparin-Binding Protein in the Diagnosis of Acute Exacerbation of Chronic Obstructive Pulmonary Disease. *Contrast media & molecular imaging* 2021, 2021:3800211.
<https://doi.org/10.1155/2021/3800211>
PMid:35024012 PMCID:PMC8716236
 27. Dou QL, Liu J, Zhang W, Wang CW, Gu Y, Li N, Hu R, Hsu WT, Huang AH, Tong HS et al: Dynamic changes in heparin-binding protein as a prognostic biomarker for 30-day mortality in sepsis patients in the intensive care unit. *Scientific reports* 2022, 12(1):10751.
<https://doi.org/10.1038/s41598-022-14827-1>
PMid:35750778 PMCID:PMC9232494
 28. F. T. Alaaraji S: Is there a Correlation between Monocyte Chemoattractant Protein-1 with Autotaxin, Azurocidin-1, Apolipoprotein C-III and Elastase-2 in Male Iraqi Acute Myocardial Infarction Patients? *Biomedical and Pharmacology Journal* 2019, 12(04):2105-2121.
<https://doi.org/10.13005/bpj/1846>
 29. Halldorsdottir HD, Eriksson J, Persson BP, Herwald H, Lindbom L, Weitzberg E, Oldner A: Heparin-binding protein as a biomarker of post-injury sepsis in trauma patients. *Acta anaesthesiologica Scandinavica* 2018, 62(7):962-973.
<https://doi.org/10.1111/aas.13107>
PMid:29569247
 30. Han X, Dou Q, Zhu Y, Ling P, Shen YH, Liu J, Zhang Z, Zhou Y, Fan M, Huang SS et al: Heparin-binding protein-enhanced quick SOFA score improves mortality prediction in sepsis patients. *Frontiers in medicine* 2022, 9:926798.
<https://doi.org/10.3389/fmed.2022.926798>
PMid:36035420 PMCID:PMC9402998
 31. Havelka A, Sejersen K, Venge P, Pauksens K, Larsson A: Calprotectin, a new biomarker for diagnosis of acute respiratory infections. *Scientific reports* 2020, 10(1):4208.
<https://doi.org/10.1038/s41598-020-61094-z>
PMid:32144345 PMCID:PMC7060262
 32. Ipek E, Yolcu M, Yildirim E, Altinkaynak K, Ozbek Sebin S, Kalkan K, Gulcu O, Ermiş E, Ozturk M: A Novel Marker of Inflammation: Azurocidin in Patients with ST Segment Elevation Myocardial Infarction. *International journal of molecular sciences* 2018, 19(12).
<https://doi.org/10.3390/ijms19123797>
PMid:30501029 PMCID:PMC6321077
 33. Johansson J, Brattström O, Sjöberg F, Lindbom L, Herwald H, Weitzberg E, Oldner A: Heparin-binding protein (HBP): an early marker of respiratory failure after trauma? *Acta anaesthesiologica Scandinavica* 2013, 57(5):580-586.
<https://doi.org/10.1111/aas.12070>
PMid:23320546
 34. Kandil M, Khalil G, El-Attar E, Shehata G, Hassan S: Accuracy of heparin binding protein: as a new marker in prediction of acute bacterial meningitis. *Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]* 2018, 49 Suppl 1(Suppl 1):213-219.
<https://doi.org/10.1016/j.bjm.2018.05.007>
PMid:30166267 PMCID:PMC6328899
 35. Katsaros K, Renieris G, Safarika A, Adami EM, Gkavogianni T, Giannikopoulos G, Solomonidi N, Halvatzis S, Koutelidakis IM, Tsokos N et al: Heparin Binding Protein for the Early Diagnosis and Prognosis of Sepsis in the Emergency Department: The Prompt Multicenter Study. *Shock (Augusta, Ga)* 2022, 57(4):518-525.
<https://doi.org/10.1097/SHK.0000000000001900>
PMid:34907118
 36. Kjölvmærk C, Pålman LI, Åkesson P, Linder A: Heparin-binding protein: a diagnostic biomarker of urinary tract infection in adults. *Open forum infectious diseases* 2014, 1(1):ofu004.
<https://doi.org/10.1093/ofid/ofu004>
PMid:25734078 PMCID:PMC4324176
 37. Kjölvmærk C, Tschernij E, Öberg J, Pålman LI, Linder A, Åkesson P: Distinguishing asymptomatic bacteriuria from urinary tract infection in the elderly - the use of urine levels of heparin-binding protein and interleukin-6. *Diagnostic microbiology and infectious disease* 2016, 85(2):243-248.
<https://doi.org/10.1016/j.diagmicrobio.2016.03.005>
PMid:27039283
 38. Kong D, Lei Z, Wang Z, Yu M, Li J, Chai W, Zhao X: A novel HCP (heparin-binding protein-C reactive protein-procalcitonin) inflammatory composite model can predict severe acute pancreatitis. *Scientific reports* 2023, 13(1):9440.
<https://doi.org/10.1038/s41598-023-36552-z>
PMid:37296194 PMCID:PMC10256784
 39. Kong Y, Ye Y, Ma J, Shi G: Accuracy of heparin-binding protein for the diagnosis of nosocomial meningitis and ventriculitis. *Critical care (London, England)* 2022, 26(1):56.

- <https://doi.org/10.1186/s13054-022-03929-x>
PMid:35260175 PMCID:PMC8903701
40. Leppilahti JM, Hernández-Ríos PA, Gamonal JA, Tervahartiala T, Brignardello-Petersen R, Mantyla P, Sorsa T, Hernández M: Matrix metalloproteinases and myeloperoxidase in gingival crevicular fluid provide site-specific diagnostic value for chronic periodontitis. *Journal of clinical periodontology* 2014, 41(4):348-356.
<https://doi.org/10.1111/jcpe.12223>
PMid:24382144
 41. Lin Q, Shen J, Shen L, Zhang Z, Fu F: Increased plasma levels of heparin-binding protein in patients with acute respiratory distress syndrome. *Critical care (London, England)* 2013, 17(4):R155.
<https://doi.org/10.1186/cc12834>
PMid:23883488 PMCID:PMC4056599
 42. Linder A, Akesson P, Brink M, Studahl M, Björck L, Christensson B: Heparin-binding protein: a diagnostic marker of acute bacterial meningitis. *Critical care medicine* 2011, 39(4):812-817.
<https://doi.org/10.1097/CCM.0b013e318206c396>
PMid:21200320
 43. Linder A, Arnold R, Boyd JH, Zindovic I, Lange A, Paulsson M, Nyberg P, Russell JA, Pritchard D et al: Heparin-Binding Protein Measurement Improves the Prediction of Severe Infection With Organ Dysfunction in the Emergency Department. *Critical care medicine* 2015, 43(11):2378-2386.
<https://doi.org/10.1097/CCM.0000000000001265>
PMid:26468696 PMCID:PMC4603368
 44. Ma H, Liu H, Wu C, Huang L: Diagnostic Value of Serum Heparin Binding Protein, Blood Lactic Acid Combined with hs-CRP in Sepsis and Its Relationship with Prognosis. Evidence-based complementary and alternative medicine : eCAM 2021, 2021:5023733.
<https://doi.org/10.1155/2021/5023733>
PMid:34795784 PMCID:PMC8594982
 45. Ma J, Lu Q, Tu S, Miao X, Zhao J: A diagnostic test: combined detection of heparin-binding protein, procalcitonin, and C-reactive protein to improve the diagnostic accuracy of bacterial respiratory tract infections. *Journal of thoracic disease* 2022, 14(3):721-728.
<https://doi.org/10.21037/jtd-22-260>
PMid:35399251 PMCID:PMC8987818
 46. Mellhammar L, Thelaus L, Elén S, Fisher J, Linder A: Heparin binding protein in severe COVID-19-A prospective observational cohort study. *PloS one* 2021, 16(4):e0249570.
<https://doi.org/10.1371/journal.pone.0249570>
PMid:33822821 PMCID:PMC8023466
 47. Meng Y, Zhang L, Huang M, Sun G: Blood heparin-binding protein and neutrophil-to-lymphocyte ratio as indicators of the severity and prognosis of community-acquired pneumonia. *Respiratory medicine* 2023, 208:107144.
<https://doi.org/10.1016/j.rmed.2023.107144>
PMid:36736745
 48. Nalmpantis D, Gatou A, Fragkioudakis I, Margariti A, Skoura L, Sakellari D: Azurocidin in gingival crevicular fluid as a potential biomarker of chronic periodontitis. *Journal of periodontal research* 2020, 55(2):209-214.
<https://doi.org/10.1111/jre.12703>
PMid:31608993
 49. Namiduru E NM, Karaoglan I, Erbağci E: Heparin Binding Protein in Early Differential Diagnosis of Bacterial Meningitis. *Indian Journal of Clinical Biochemistry* 2022.
<https://doi.org/10.1007/s12291-022-01066-4>
PMid:38223001 PMCID:PMC10784236
 50. Obreja M, Miftode EG, Stoleriu I, Constantinescu D, Văță A, Leca D, Cianga CM, Dorneanu OS, Pavel-Tanasa M, Cianga P: Heparin-Binding Protein (HBP), Neutrophil Gelatinase-Associated Lipocalin (NGAL) and S100 Calcium-Binding Protein B (S100B) Can Confirm Bacterial Meningitis and Inform Adequate Antibiotic Treatment. *Antibiotics (Basel, Switzerland)* 2022, 11(6).
<https://doi.org/10.3390/antibiotics11060824>
PMid:35740230 PMCID:PMC9220165
 51. Olinder J, Börjesson A, Norrman J, West T, Carlström J, Gustafsson A, Annborn M, Herwald H, Rydén C: Hecpudin discriminates sepsis from other critical illness at admission to intensive care. *Scientific reports* 2022, 12(1):14857.
<https://doi.org/10.1038/s41598-022-18826-0>
PMid:36050405 PMCID:PMC9434539
 52. Pajenda S, Figurek A, Wagner L, Gerges D, Schmidt A, Herkner H, Winnicki W: Heparin-binding protein as a novel biomarker for sepsis-related acute kidney injury. *PeerJ* 2020, 8:e10122.
<https://doi.org/10.7717/peerj.10122>
PMid:33088624 PMCID:PMC7568480
 53. Paulsson M, Thelaus L, Riesbeck K, Qvarfordt I, Smith ME, Lindén A, Linder A: Heparin-binding protein in lower airway samples as a biomarker for pneumonia. *Respiratory research* 2021, 22(1):174.
<https://doi.org/10.1186/s12931-021-01764-2>
PMid:34103069 PMCID:PMC8185500
 54. Ristagno G, Masson S, Tiainen M, Bendel S, Bernasconi R, Varpula T, Milani V, Vaahersalo J, Magnoli M, Spanuth E et al: Elevated plasma heparin-binding protein is associated with early death after resuscitation from cardiac arrest. *Critical care (London, England)* 2016, 20(1):251.
<https://doi.org/10.1186/s13054-016-1412-4>
PMid:27497949 PMCID:PMC4976065
 55. Saridaki M, Metallidis S, Grigoropoulou S, Vrentzos E, Lada M, Argyraki K, Tsachouridou O, Georgiadou A, Vasishta A, Giamarellos-Bourboulis EJ: Integration of heparin-binding protein and interleukin-6 in the early prediction of respiratory failure and mortality in pneumonia by SARS-CoV-2 (COVID-19). *European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology* 2021, 40(7):1405-1412.
<https://doi.org/10.1007/s10096-020-04145-7>
PMid:33515095 PMCID:PMC7846268
 56. Shu W, Wan J, Yang X, Chen J, Yang Q, Liu F, Xia L: Heparin-Binding Protein Levels at Admission and Within 24 h Are Associated with Persistent Organ Failure in Acute Pancreatitis. *Digestive diseases and sciences* 2021, 66(10):3597-3603.
<https://doi.org/10.1007/s10620-020-06660-1>
PMid:33094452
 57. Sjöbeck M, Sternby H, Herwald H, Thorlacius H, Regnér S: Heparin-binding protein is significantly increased in acute pancreatitis. *BMC gastroenterology* 2021, 21(1):337.
<https://doi.org/10.1186/s12876-021-01910-6>
PMid:34454419 PMCID:PMC8403433
 58. Stjärne Aspelund A, Hammarström H, Inghammar M, Larsson H, Hansson L, Christensson B, Pählman LI: Heparin-binding protein, lysozyme, and inflammatory cytokines in bronchoalveolar lavage fluid as diagnostic tools for pulmonary infection in lung transplanted patients. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons* 2018, 18(2):444-452.
<https://doi.org/10.1111/ajt.14458>
PMid:28787761 PMCID:PMC5813223
 59. Sun JK, Shen X, Sun XP, Wang X, Zhang WH, Shi QK, Mu XW: Heparin-binding protein as a biomarker of gastrointestinal dysfunction in critically ill patients: a retrospective cross-sectional study in China. *BMJ open* 2020, 10(7):e036396.
<https://doi.org/10.1136/bmjopen-2019-036396>
PMid:32624474 PMCID:PMC7337894
 60. Tang J, Yuan H, Wu YL, Fu S, Pan XY: The Predictive Value of Heparin-Binding Protein and D-Dimer in Patients with Sepsis. *International journal of general medicine* 2023, 16:2295-2303.
<https://doi.org/10.2147/IJGM.S409328>
PMid:37304904 PMCID:PMC10257474
 61. Temiz A AK, Albayrak Y, Özdemir Y, Şebini S, anrikulu C: Prognostic importance of plasma heparin binding protein in the diagnosis of acute appendicitis. *Annals of Clinical and Analytical Medicine* 2019, 10(04).
<https://doi.org/10.4328/ACAM.6004>
 62. Tian R, Chen X, Yang C, Teng J, Qu H, Liu HL: Serum Heparin-Binding Protein as a Potential Biomarker to Distinguish Adult-Onset Still's Disease From Sepsis. *Frontiers in immunology* 2021, 12:654811.
<https://doi.org/10.3389/fimmu.2021.654811>
PMid:33868298 PMCID:PMC8044511
 63. Tverring J, Vaara ST, Fisher J, Poukkanen M, Pettilä V, Linder A: Heparin-binding protein (HBP) improves prediction of sepsis-related acute kidney injury. *Annals of intensive care* 2017, 7(1):105.
<https://doi.org/10.1186/s13613-017-0330-1>
PMid:29047023 PMCID:PMC5647316
 64. Wang Z, Chang B, Zhang Y, Chen J, Xie F, Xiang Y, Liu T, Li Y: Clinical value of serum sTREM-1 and HBP levels in combination with traditional inflammatory markers in diagnosing hospital-acquired pneumonia in elderly. *BMC infectious diseases* 2022, 22(1):773.
<https://doi.org/10.1186/s12879-022-07758-9>
PMid:36195852 PMCID:PMC9531631
 65. Widén J, Cederberg D, Linder A, Westman G: Heparin-binding protein as a marker of ventriculostomy related infection and central nervous system inflammation in neuro-intensive care. *Clinical neurology and neurosurgery* 2023, 229:107752.
<https://doi.org/10.1016/j.clineuro.2023.107752>
PMid:37156040

66. Wu KA, Wu CC, Liu YC, Hsueh PC, Chin CY, Wang CL, Chu CM, Shih LJ, Yang CY: Combined serum biomarkers in the noninvasive diagnosis of complicated parapneumonic effusions and empyema. *BMC pulmonary medicine* 2019, 19(1):108.
<https://doi.org/10.1186/s12890-019-0877-8>
PMid:31215423 PMCID:PMC6582530
67. Ying Li, Ke Feng WC, Jing Qiao, Meng Zhao: High levels of crp, pct and hbp are correlated with pneumonia secondary sepsis. *Acta Medica Mediterranea* 2020, 36:2173-2177.
68. Zhang S ZY, Shi B, Chen X, Zhang H, Li C, Jun Zhang, Hong P, Gao S: Evaluation of heparin-binding protein and or procalcitonin levels in the diagnosis of bacterial intracranial infection using receiver operating characteristic (ROC) curve value. *Int J Clin Exp Med* 2019, 12(6):7778-7782.
69. Zhong Y, Yu Z, Wang L, Yang X: Combined detection of procalcitonin, heparin-binding protein, and interleukin-6 is a promising assay to diagnose and predict acute pancreatitis. *Journal of clinical laboratory analysis* 2021, 35(8):e23869.
<https://doi.org/10.1002/jcla.23869>
PMid:34151489 PMCID:PMC8373338
70. Zhou Y, Liu Z, Huang J, Li G, Li F, Cheng Y, Xie X, Zhang J: Usefulness of the heparin-binding protein level to diagnose sepsis and septic shock according to Sepsis-3 compared with procalcitonin and C reactive protein: a prospective cohort study in China. *BMJ open* 2019, 9(4):e026527.
<https://doi.org/10.1136/bmjopen-2018-026527>
PMid:31015272 PMCID:PMC6502053
71. Tydén J, Herwald H, Hultin M, Walldén J, Johansson J: Heparin-binding protein as a biomarker of acute kidney injury in critical illness. *Acta anaesthesiologica Scandinavica* 2017, 61(7):797-803.
<https://doi.org/10.1111/aas.12913>
PMid:28585315
72. Chen S, Zhang C, Hong G, Wang Q, Lian M: Meta-analysis of the diagnostic efficacy of heparin binding protein in adult sepsis. *Zhonghua wei zhong bing ji jiu yi xue* 2019, 31(11):1330-1334.
73. Tapper H, Karlsson A, Mörgelin M, Flodgaard H, Herwald H: Secretion of heparin-binding protein from human neutrophils is determined by its localization in azurophilic granules and secretory vesicles. *Blood* 2002, 99(5):1785-1793.
<https://doi.org/10.1182/blood.V99.5.1785>
PMid:11861296
74. Wu YL, Yo CH, Hsu WT, Qian F, Wu BS, Dou QL, Lee CC: Accuracy of Heparin-Binding Protein in Diagnosing Sepsis: A Systematic Review and Meta-Analysis. *Critical care medicine* 2021, 49(1):e80-e90.
<https://doi.org/10.1097/CCM.0000000000004738>
PMid:33196528
75. Chen M, Yuan J, Yang Z, Cai G: Value of heparin-binding protein in diagnosis of sepsis in adult patients: a Meta-analysis. *Zhonghua wei zhong bing ji jiu yi xue* 2019, 31(10):1224-1230.
76. Fisher J, Kahn F, Wiebe E, et al. The Dynamics of Circulating Heparin-Binding Protein: Implications for Its Use as a Biomarker. *J Innate Immun.* 2022;14(5):447-460.
<https://doi.org/10.1159/000521064>
PMid:34965528 PMCID:PMC9485916
77. Chen Y, Ma T. Hematologic cancers and infections: how to detect infections in advance and determine the type? *Front Cell Infect Microbiol.* 2024 Nov 4;14:1476543.
<https://doi.org/10.3389/fcimb.2024.1476543>
PMid:39559703 PMCID:PMC11570547
78. Kostic I., Gurrieri C., Piva E., Semenzato G., Plebani M., Caputo I., Vianello F. Comparison of presepsin, procalcitonin, interleukin-8 and C-reactive protein in predicting bacteraemia in febrile neutropenic adult patients with haematological malignancies. *Mediterr J Hematol Infect Dis* 2019, 11(1): e2019047,
<https://doi.org/10.4084/mjhid.2019.047>
PMid:31528313 PMCID:PMC6736337